SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 40 200 KRW 3.61% Market Closed
Market Cap: 3.2T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SK Bioscience Co Ltd stock under the Base Case scenario is 65 654.44 KRW. Compared to the current market price of 40 200 KRW, SK Bioscience Co Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
65 654.44 KRW
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.8
P/S
P/S
Price to Sales
11.8
vs History
78
vs Industry
39
Median 3Y
12.4
Median 5Y
12.9
Industry
6.9
Forward
4.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
46.1
Median 5Y
68.1
Industry
22.4
Forward
-40.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
3
Median 3Y
31.5
Median 5Y
33.8
Industry
19.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-25.6
Median 5Y
-20.6
Industry
23.2
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
96
vs Industry
43
Median 3Y
3
Median 5Y
3.2
Industry
2.5
More Details
8.9
EV/S
EV/S
Enterprise Value to Sales
8.9
vs History
76
vs Industry
38
Median 3Y
9.5
Median 5Y
9.9
Industry
7.5
Forward
3.7
More Details
76.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
76.8
vs History
11
vs Industry
11
Median 3Y
22.8
Median 5Y
24.6
Industry
8.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
1
Median 3Y
19.3
Median 5Y
30.7
Industry
4
Forward
-109.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
13.3
Median 5Y
20.2
Industry
3.7
Forward
-22.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
3
Median 3Y
23.2
Median 5Y
28
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-7.6
Industry
3.4
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
96
vs Industry
50
Median 3Y
6
Median 5Y
6.4
Industry
4.6
More Details

Multiples Across Competitors

Competitors Multiples
SK Bioscience Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
SK Bioscience Co Ltd
KRX:302440
3.1T KRW 11.8 -62.8 -26.7 -17.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 067 711 -166 671.6 -202 392.5 -200 083
US
Abbvie Inc
NYSE:ABBV
324.1B USD 5.7 76.4 15.2 23
US
Amgen Inc
NASDAQ:AMGN
144.7B USD 4.3 35.3 14.7 26.1
US
Gilead Sciences Inc
NASDAQ:GILD
120.7B USD 4.2 251.5 10 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.3B USD 9.9 -204 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 008.9 -512.6 -558.2 -543.3
AU
CSL Ltd
ASX:CSL
116.2B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
58.6B USD 4.1 13.2 7.8 8.7
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.3 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
28.7B EUR 15 39.5 -2 202.9 -1 477
P/S Multiple
Revenue Growth P/S to Growth
KR
SK Bioscience Co Ltd
KRX:302440
Average P/S: 3 188 163.6
11.8
39%
0.3
FR
Pharnext SCA
OTC:PNEXF
35 067 711
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.2
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 008.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.1
6%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
15
39%
0.4
P/E Multiple
Earnings Growth PEG
KR
SK Bioscience Co Ltd
KRX:302440
Average P/E: 73.9
Negative Multiple: -62.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
76.4
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
35.3
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
251.5
187%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -204 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
10%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
39.5
28%
1.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
SK Bioscience Co Ltd
KRX:302440
Average EV/EBITDA: 14.4
Negative Multiple: -26.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 392.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
14.7
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
7.8
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 202.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
SK Bioscience Co Ltd
KRX:302440
Average EV/EBIT: 19.1
Negative Multiple: -17.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 083 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.1
31%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
11%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.7
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 477 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.